This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy?
by Ahan Chakraborty
CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.
MRK Beats Q3 Earnings Estimates, Narrows 2025 Sales View, Stock Down
by Zacks Equity Research
Merck tops Q3 earnings and revenue estimates on strong oncology, new drugs and animal health sales, while narrowing its 2025 revenue outlook.
Amarin's Q3 Earnings Lag Estimates, Revenues Beat, Stock Down
by Zacks Equity Research
AMRN's third-quarter earnings fall short of expectations, but stronger U.S. Vascepa sales push revenues above estimates.
United Therapeutics Q3 Earnings Beat Estimates, Revenues Miss Mark
by Zacks Equity Research
UTHR beats Q3 earnings forecasts on solid Tyvaso and Orenitram growth, while revenues fall shy of estimates.
RGEN'S Q3 Earnings Beat Estimates, Revenues Surge Y/Y, Stock Down
by Zacks Equity Research
Repligen posts strong Q3 results with revenue growth and an earnings beat, yet shares dip as tighter EPS guidance tempers investor optimism.
4 High-Earnings Yield Value Picks Ahead of Potential Fed Rate Cut
by Rimmi Singhi
As the Fed readies for another rate cut, value investors could turn to high-earnings-yield stocks like AUGO, CMC, PARR and CRMD.
Should Investors Buy CorMedix Stock Ahead of Q3 Earnings Report?
by Ahan Chakraborty
CRMD's Q3 momentum, fueled by DefenCath's strong uptake and Melinta's revenue boost, positions the stock for continued growth.
SNY's Efdoralprin Alfa Meets Key Endpoints in Rare Disease Study
by Zacks Equity Research
Sanofi's efdoralprin alfa meets all key endpoints in a global phase II study, showing potential as a first restorative recombinant therapy for AATD.
Earnings Estimates Rising for CorMedix (CRMD): Will It Gain?
by Zacks Equity Research
CorMedix (CRMD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Wall Street Analysts See a 68.59% Upside in CorMedix (CRMD): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 68.6% in CorMedix (CRMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
CorMedix (CRMD) Surges 19.5%: Is This an Indication of Further Gains?
by Zacks Equity Research
CorMedix (CRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
How Will DefenCath Aid CRMD's Top Line in the Upcoming Q3 Results?
by Ahan Chakraborty
CorMedix's DefenCath, the first FDA-approved antimicrobial catheter lock, is expected to drive Q3 growth as new Melinta drugs add to momentum.
Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX
by Zacks Equity Research
ATXS stock jumps 37% after agreeing to a $700 million cash-and-stock buyout by BioCryst, boosting the latter's HAE treatment pipeline.
CorMedix Stock Plunges 16% in a Month: Should Investors Buy the Dip?
by Ahan Chakraborty
CRMD shares slip 16%, but rising DefenCath sales and the Melinta deal can set the stage for renewed growth.
FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months
by Zacks Equity Research
Denali Therapeutics faces an FDA review delay for its Hunter syndrome drug, pushing potential approval of tividenofusp alfa to April 2026.
Will CorMedix's DefenCath Edge Last If Bigger Heparin Rivals Close In?
by Ahan Chakraborty
CRMD's DefenCath gives the company a first-mover edge in CRBSI prevention, but looming heparin giants test how long its lead can last.
GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal
by Zacks Equity Research
Genmab stock surges 21.9% after striking an $8 billion deal to buy Merus, adding a late-stage cancer treatment candidate to its proprietary oncology pipeline.
ILMN Stock Set to Benefit From the Launch of New BioInsight Division
by Zacks Equity Research
Illumina launches BioInsight to harness multiomic data, accelerate drug discovery, and boost disease diagnosis.
ANGO Stock Gains Following Q1 Earnings Beat, Gross Margin Improves
by Zacks Equity Research
AngioDynamics posts narrower-than-expected Q1 loss, 12% revenue growth and margin gains; it also raises FY26 sales outlook, sending shares higher.
CDTX Stock Soars 218% YTD on Positive Updates From Influenza Program
by Zacks Equity Research
Cidara Therapeutics' shares surge 218% this year after its flu candidate CD388 hits key mid-stage study goals and advances into pivotal testing.
QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study
by Zacks Equity Research
uniQure N.V. shares surge nearly 248% after its gene therapy candidate, AMT-130, met key goals in a pivotal Huntington's disease study.
ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure
by Zacks Equity Research
Acadia Pharmaceuticals stock tumbles 10% after its phase III hyperphagia study failure, but growth remains driven by Nuplazid, Daybue and a robust pipeline.
REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug
by Zacks Equity Research
Replimune stock dives 54% over three months after the FDA rejects its RP1/Opdivo melanoma drug filing, delaying its first potential product launch.
CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick?
by Ahan Chakraborty
CorMedix and Mirum Pharmaceuticals are advancing niche therapies with strong launches, rising sales and strategic acquisitions shaping their growth.
SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU
by Zacks Equity Research
Sanofi/Regeneron's Dupixent wins CHMP backing for chronic spontaneous urticaria in the EU, paving the way for expanded treatment options.